Norris Medicines Ltd Stock Falls to 52-Week Low of Rs.12.87

Recent Price Movement and Market Context

On the trading day, Norris Medicines Ltd’s stock fell by 9.03%, closing at Rs.12.87, which represents the lowest price level in the past year. The intraday low also touched Rs.12.87, with the stock experiencing high volatility of 5.92% based on the weighted average price. This decline came amid a broader market weakness, with the Sensex falling 503.35 points (-1.08%) to 81,291.30 after a negative opening. The Sensex itself has been on a three-week losing streak, down 5.21% over that period.

The stock’s performance today notably lagged its sector, Trading & Distributors, by 9.53%, and it has now recorded losses for four consecutive trading sessions, cumulatively falling 16.97% during this stretch. Norris Medicines is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a sustained bearish trend.

Long-Term Performance and Relative Comparison

Over the last 12 months, Norris Medicines Ltd’s stock has delivered a negative return of 44.40%, a stark contrast to the Sensex’s positive 7.31% gain over the same period. The stock’s 52-week high was Rs.24.65, underscoring the magnitude of the decline from its peak. This underperformance extends beyond the last year, with the stock lagging the BSE500 index over the past three years, one year, and three months, indicating persistent challenges in maintaining market value relative to broader benchmarks.

Financial Metrics and Fundamental Assessment

Norris Medicines Ltd’s financial profile continues to reflect considerable headwinds. The company’s Mojo Score stands at 12.0 with a Mojo Grade of Strong Sell, upgraded from Sell on 30 Jun 2025, indicating deteriorated fundamentals and market sentiment. The Market Cap Grade is 4, signalling a relatively low market capitalisation quality.

One of the critical concerns is the company’s negative book value, which points to weak long-term fundamental strength. Over the past five years, net sales have declined at an annualised rate of 2.13%, while operating profit has remained flat, showing no growth. The company’s debt position is notable, with an average Debt to Equity ratio of zero, indicating a high debt burden relative to equity, which adds to financial risk.

Quarterly results for September 2025 further highlight challenges, with PBDIT (Profit Before Depreciation, Interest and Taxes) at a low of Rs.-0.49 crore and PBT (Profit Before Tax) excluding other income at Rs.-0.72 crore. Earnings per share (EPS) for the quarter also hit a low of Rs.-0.73. The company’s EBITDA remains negative, underscoring ongoing profitability pressures.

Valuation and Risk Profile

The stock is currently trading at valuations considered risky compared to its historical averages. Over the past year, profits have declined by 71%, exacerbating concerns about the company’s earnings quality and sustainability. This has contributed to the stock’s steep price decline and its classification as a Strong Sell by MarketsMOJO.

Majority shareholding remains with non-institutional investors, which may influence liquidity and trading dynamics. The stock’s high volatility and consistent underperformance relative to sector and market indices reflect the cautious stance adopted by market participants.

Sector and Market Environment

The Trading & Distributors sector, to which Norris Medicines belongs, has also faced pressure, with the NIFTY MEDIA index hitting a new 52-week low on the same day. The broader market environment remains subdued, with the Sensex trading below its 50-day moving average, although the 50DMA remains above the 200DMA, suggesting some longer-term support for the market overall.

Despite the challenging environment, Norris Medicines Ltd’s performance has been notably weaker than both its sector and the broader market, reflecting company-specific issues alongside general market trends.

Summary of Key Data Points

• New 52-week low price: Rs.12.87 (21 Jan 2026)

• Day’s decline: -9.03%

• Four-day consecutive fall: -16.97% cumulative

• 1-year return: -44.40%

• Sensex 1-year return: +7.31%

• 52-week high: Rs.24.65

• Mojo Score: 12.0 (Strong Sell)

• Debt to Equity ratio (average): 0 times

• Quarterly PBDIT: Rs.-0.49 crore

• Quarterly PBT less other income: Rs.-0.72 crore

• Quarterly EPS: Rs.-0.73

• Intraday volatility: 5.92%

The stock’s sustained decline to a new 52-week low and its financial metrics highlight the challenges Norris Medicines Ltd faces in regaining investor confidence and market stability.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →